pharmaceutical innovation Archives

Comic-style illustration titled “The Fund-Raisers!” showing investors, a biotech innovation globe, a Forbion shield and laboratories, with a speech bubble announcing “2.6 billion raised.”

Forbion’s $2.6 Billion Biotech Raise Signals Smart Money Is Backing the Next Wave of Medicines -( $IBB $LLY $XBI )

by John F. Heerdink, Jr. October 8, 2026 645Views 0Likes

Two new funds, institutional backing and a pharmaceutical heavyweight give the European life sciences investor fresh capital to turn promising science into investable businesses. Biotechnology has never suffered from a shortage of ambitious ideas. Financing them is another matter. Forbion has just…

Illustration of a futuristic biotech bear in a forest alongside a princess and armored knight, symbolizing the growing investment opportunity in durable drug-delivery therapies for retinal disease, eosinophilic esophagitis, and Parkinson’s disease.

Biotech’s Durability Trade Is Getting Interesting: Kodiak, Eupraxia and Serina Put the Burden of Treatment in Focus -( $ABBV $EPRX $IBB $KOD $SER $XBI )

by John F. Heerdink, Jr. September 28, 2026 501Views 0Likes

The biotech market has long rewarded breakthrough efficacy. Increasingly, it is also rewarding something patients and physicians understand with unusual clarity: less treatment burden. Fresh clinical updates from Kodiak Sciences Inc. (NASDAQ: KOD), Eupraxia Pharmaceuticals Inc. (NASDAQ: EPRX), and Serina Therapeutics Inc. (NYSE…

Illustration of a brain transitioning from a cracked, burdened form to a vibrant neural network, symbolizing advanced Parkinson’s disease treatment innovation, continuous dopamine therapy and improved drug delivery.

Serina Therapeutics Advances SER-252 in Advanced Parkinson’s Disease as Continuous Therapy Market Expands -( $ABBV $SER )

by John F. Heerdink, Jr. September 25, 2026 503Views 0Likes

SER-252 enters Cohort 2 with blinded early observations that support the central premise: sustained delivery of a proven Parkinson’s medicine may be far more valuable when it asks less of patients and caregivers. In biotechnology, there are moonshots, and then there are…

Tribe Public CEO Presentation and Q&A webinar graphic featuring Serina Therapeutics CEO Steven Ledger, NYSE: SER, promoting “A New Approach to Advanced Parkinson’s Disease: Exploring SER-252’s Clinical Progress,” with a global network map, molecular imagery, and Register Now call to action.

Serina Therapeutics Brings a Fresh Dose of Momentum to Advanced Parkinson’s Care -( $SER $PFE $XBI )

by John F. Heerdink, Jr. September 21, 2026 374Views 0Likes

Serina Therapeutics, Inc. (NYSE American: SER) is approaching a consequential clinical milestone with SER-252, its long-acting POZ-apomorphine candidate for advanced Parkinson’s disease, now advancing into Cohort 2 of a registrational Phase 1b study. For many, the appeal is not simply that Serina is pursuing…

Digital Nasdaq billboard in Times Square highlighting Eupraxia Pharmaceuticals (NASDAQ: EPRX), its Nasdaq Global Select Market upgrade, and the upcoming eosinophilic esophagitis clinical-data catalyst.

Eupraxia Pharmaceuticals’ Nasdaq Upgrade Sets the Table for a High-Stakes EoE Catalyst -( $EPRX $SNY $XBI )

by John F. Heerdink, Jr. September 8, 2026 304Views 0Likes

Eupraxia Pharmaceuticals Inc. (NASDAQ: EPRX; TSX: EPRX) has moved up to the Nasdaq Global Select Market just as its lead clinical program approaches a pivotal Phase 2b interim data event. For many, the timing is rather tidy: the company is pairing greater market…

Illustration of an older man with Parkinson’s symptoms beside a laboratory researcher holding a syringe, with a large brain diagram showing dopamine pathways, sustained drug release, motor control, and Serina Therapeutics’ Parkinson’s disease drug-delivery innovation.

Serina Therapeutics: A Parkinson’s Story Where Better Drug Delivery Could Become the Main Event -( $PFE $SER $XBI )

by John F. Heerdink, Jr. September 8, 2026 307Views 0Likes

Serina Therapeutics, Inc. (NYSE American: SER) is building a potentially compelling clinical and platform-driven story around a familiar biotech proposition: take a medicine with demonstrated utility, improve the way it behaves in the body, and create a product patients may find meaningfully…

Tag: pharmaceutical innovation

Forbion’s $2.6 Billion Biotech Raise Signals Smart Money Is Backing the Next Wave of Medicines -( $IBB $LLY $XBI )

Biotech’s Durability Trade Is Getting Interesting: Kodiak, Eupraxia and Serina Put the Burden of Treatment in Focus -( $ABBV $EPRX $IBB $KOD $SER $XBI )

Serina Therapeutics Advances SER-252 in Advanced Parkinson’s Disease as Continuous Therapy Market Expands -( $ABBV $SER )

Serina Therapeutics Brings a Fresh Dose of Momentum to Advanced Parkinson’s Care -( $SER $PFE $XBI )

Eupraxia Pharmaceuticals’ Nasdaq Upgrade Sets the Table for a High-Stakes EoE Catalyst -( $EPRX $SNY $XBI )

Serina Therapeutics: A Parkinson’s Story Where Better Drug Delivery Could Become the Main Event -( $PFE $SER $XBI )

Your Guide To Staying Informed In The Markets